High expression of Myosin 1g in pediatric acute lymphoblastic leukemia.
Myosin 1g
acute lymphoblastic leukemia
biomarker
high risk
pediatric
Journal
Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965
Informations de publication
Date de publication:
14 Sep 2021
14 Sep 2021
Historique:
received:
13
03
2021
accepted:
13
08
2021
entrez:
22
9
2021
pubmed:
23
9
2021
medline:
23
9
2021
Statut:
epublish
Résumé
Acute Lymphoblastic Leukemia (ALL) is the most frequent cancer in pediatric population. Although the treatment has improved and almost 85% of the children are cured about 20% suffer relapse, therefore finding molecules that participate in the pathogenesis of the disease for the identification of relapse and patients at risk is an urgent unmet need. Class I myosins are molecular motors involved in membrane tension, endocytosis, phagocytosis and cell migration and recently they have been shown important for development and aggressiveness of diverse cancer types, however Myo1g an hematopoietic specific myosin has not been studied in cancer so far. We evaluated the expression of Myo1g by qRT-PCR, Immunocytochemistry and Immunofluorescence in a cohort of 133 ALL patients and correlated the expression at diagnosis and after treatment with clinical features and treatment outcomes. We found high expression levels of Myo1g in Peripheral Blood Mononuclear Cells (PBMCs) from patients with ALL at diagnosis and those levels decreased after complete remission; furthermore, we found an increase in Myo1g expression on patients with 9:22 translocation and those who relapse. This study show that Myo1g is over expressed in ALL and that may participate in the pathogenesis of the disease specially in high-risk patients.
Identifiants
pubmed: 34548909
doi: 10.18632/oncotarget.28055
pii: 28055
pmc: PMC8448507
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1937-1945Informations de copyright
Copyright: © 2021 Estrada-Abreo et al.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST Authors have no conflicts of interest to declare.
Références
Proc Natl Acad Sci U S A. 2012 Jan 31;109(5):1530-5
pubmed: 22307608
Exp Cell Res. 2014 Apr 1;322(2):265-76
pubmed: 24462457
Front Immunol. 2017 Dec 11;8:1731
pubmed: 29321775
Blood Res. 2019 Mar;54(1):45-51
pubmed: 30956963
Oncotarget. 2016 Jul 19;7(29):46419-46432
pubmed: 27329840
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Gynecol Oncol. 2018 Apr;149(1):188-197
pubmed: 29395313
J Cell Sci. 2016 Jul 15;129(14):2689-95
pubmed: 27401928
Oncotarget. 2016 Jul 19;7(29):46785-46812
pubmed: 27121062
Nat Rev Mol Cell Biol. 2010 Sep;11(9):633-43
pubmed: 20729930
Biomed Res Int. 2018 Jan 16;2018:4578373
pubmed: 29581975
Cancer. 2015 Oct 15;121(20):3577-90
pubmed: 26194091
Oncol Lett. 2018 Sep;16(3):2929-2934
pubmed: 30127881
Leuk Lymphoma. 2014 Apr;55(4):737-48
pubmed: 23841506
Eur J Immunol. 2014 Mar;44(3):877-86
pubmed: 24310084
Cell Motil Cytoskeleton. 2000 Nov;47(3):163-73
pubmed: 11056519
J Immunol. 2011 Sep 15;187(6):3053-63
pubmed: 21841128
FEBS Lett. 2010 Feb 5;584(3):493-9
pubmed: 19968988
J Biol Chem. 2010 Mar 19;285(12):8675-86
pubmed: 20071333
Int J Cancer. 2013 Apr 15;132(8):1790-9
pubmed: 23002058
Mol Cancer Res. 2015 Apr;13(4):721-31
pubmed: 25421751
BMC Cancer. 2011 Aug 17;11:355
pubmed: 21846410
Cell. 2014 Jul 31;158(3):492-505
pubmed: 25083865
CA Cancer J Clin. 2014 Mar-Apr;64(2):83-103
pubmed: 24488779
Leukemia. 2014 Jul;28(7):1467-71
pubmed: 24441288
Trends Cell Biol. 2010 Jul;20(7):418-26
pubmed: 20471271
Immunol Rev. 2013 Nov;256(1):190-202
pubmed: 24117822
CA Cancer J Clin. 2019 Sep;69(5):363-385
pubmed: 31184787
J Leukoc Biol. 2016 Jun;99(6):1077-87
pubmed: 26931577
Cancer Cell. 2011 Feb 15;19(2):206-17
pubmed: 21295523
Biochem Soc Trans. 2016 Aug 15;44(4):1026-34
pubmed: 27528748
Cytoskeleton (Hoboken). 2014 Aug;71(8):447-63
pubmed: 25087729
Bioarchitecture. 2012 Sep-Oct;2(5):158-70
pubmed: 22954512